

### 11 April 2022

Questions and Answers document on the quality of homeopathic medicinal products (Q 13) - Stability

# Template for submission of comments on draft document

Written procedure decided by the HMPWG	30 May 2013
Adoption by written procedure	15 September 2013
Report of the outcome of the written procedure	21 November 2013

# Submission of comments on draft document

# **Table 1: Origin of comments**

Questions and Answers document on the quality of homeopathic medicinal products (Q 13) - Stability

Organisation or individual	Contact details (e-mail address, telephone number, name of contact person)
ECHAMP	Amandine OSET
Rue Washington 40	amandine.oset@echamp.eu
B-1050 Brussels	+32 2 649 94 40

Interested parties are invited to send comments together with a copy of the cited references.

This will facilitate the assessment of comments, suggestions and corresponding justifications.

When the reference consists of a book chapter, the copy must include the page of the book showing the year of publication.

Comments without copies of the supporting literature will not be considered.

Comments should be sent electronically and in Word format (not pdf).

Comments and the identity of the sender will be made public unless a justified objection is received at the time of the submission.

Please submit comments on each document separately.

# Table 2: Comments

### **GENERAL COMMENTS ON DRAFT DOCUMENT**

Interested party	Comment and Rationale	Outcome

### **SPECIFIC COMMENTS ON TEXT**

ECHAMP  For other approaches than the transfer of stability data of a homeopathic stock to its subsequent dilutions/triturations, it should not be necessary to include detailed descriptions of the entire approach on stability into the application dossier since this is within the responsibility of the manufacturer by GMP rules. It is seen as consensus that not all detailed GMP documents have to be included into the application dossier, since this essentially increases the workload of both, applicants and the competent authorities, especially with regard to potential variation procedures. A balanced approach would reduce regulatory burden for both sides.  Furthermore, it should be considered, that approaches, like the above, might be complex and require a lot of time and efforts to gather the necessary amount of data to create an appropriate basis for a feasible concept. Due to their complexity, established approaches often cannot simply be adapted to different requirements fixed by other competent authorities. Competent authorities should therefore be willing to accept approaches, already registered in other countries. This should also be reflected in the answer to this question.	Section number and heading	Interested party	Comment and Rationale	Outcome
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Line12-15	ECHAMP	stock to its subsequent dilutions/triturations, it should not be necessary to include detailed descriptions of the entire approach on stability into the application dossier since this is within the responsibility of the manufacturer by GMP rules. It is seen as consensus that not all detailed GMP documents have to be included into the application dossier, since this essentially increases the workload of both, applicants and the competent authorities, especially with regard to potential variation procedures. A balanced approach would reduce regulatory burden for both sides.  Furthermore, it should be considered, that approaches, like the above, might be complex and require a lot of time and efforts to gather the necessary amount of data to create an appropriate basis for a feasible concept. Due to their complexity, established approaches often cannot simply be adapted to different requirements fixed by other competent authorities. Competent authorities should therefore be willing to accept	